Implanet Sa - IMPZY STOCK NEWS

Implanet (Euronext: ALIMP) has formed a strategic partnership with Sanyou Medical, a leading Chinese spine surgery device manufacturer. The collaboration includes a distribution agreement for Implanet's JAZZ® platform in China, the largest spine surgery market, and a technological partnership to develop a new range of hybrid fixation systems for Europe. Additionally, Sanyou Medical will underwrite a proposed capital increase of up to €5 million, aimed at fulfilling Implanet's financial needs for the next year and supporting product expansion in Europe and China.

IMPLANET, a medical technology company, held its Annual General Meeting on June 9, 2022, with a quorum of 26.96%, represented by 5,305,617 shares. All resolutions were adopted. Upcoming financial events include H1 2022 revenue on July 11 and H1 2022 results on September 20. Founded in 2007, IMPLANET specializes in vertebral implants and reported a consolidated revenue of €6.1 million in 2021. They have received FDA clearance and CE mark for their JAZZ® product, reflecting their commitment to improving spinal treatment.

IMPLANET announced that its Annual General Meeting (AGM) scheduled for May 17, 2022 lacked quorum. A new AGM will be held on June 9, 2022, at 2 pm CEST in Paris. Shareholders are urged to participate to ensure a valid vote on company resolutions. Votes cast for the first AGM will be valid for the second. Shareholders can vote online starting May 27, 2022 or by post, with in-person attendance also an option. Key upcoming financial events include H1 2022 revenue on July 11, 2022 and H1 2022 results on September 20, 2022.

IMPLANET reported a significant revenue increase of €2.02 million in Q1 2022, doubling from €1.03 million in Q1 2021. This growth is attributed to a successful strategic repositioning, driven by organic growth from its JAZZ activity and the acquisition of OSD. Revenue in France rose by 169% to €0.95 million, while international sales surged by 164%. However, the U.S. experienced a decline of 10% due to COVID-related surgical postponements. The company aims to enhance its U.S. presence and complete product globalization.

Implanet reported significant financial growth for the year ending December 31, 2021, with a 58% increase in revenue to €6.14 million, driven by strong performance in the Spine business, which grew by 62%. The gross margin also rose by 46% to €3.72 million. Despite a 22% improvement in net results to -€3.09 million, the recurring operating loss widened by 31% to -€4.32 million, influenced by operational costs related to acquisitions. The company is focused on strategic expansion and new product launches in 2022.

IMPLANET announces the successful first surgeries in the United States using its ORIGIN cervical plate, a product of its merger with Orthopaedic & Spine Development (OSD). This expansion into the U.S. market, valued at $1.35 billion annually, follows FDA clearance and CE marking for the ORIGIN range. CEO Ludovic Lastennet highlights the potential for rapid growth through their enhanced product offerings, aimed at capitalizing on synergies with OSD’s distribution network. Over 7,000 plates have been sold globally since launch.

IMPLANET has announced the launch of JAZZ™ PF, a new spinal implant designed to minimize the risk of proximal junctional kyphosis (PJK) following surgery. This innovation addresses a significant market need, with an addressable annual market of almost $350 million in the United States. JAZZ™ PF has received CE marking in Europe and 510(k) clearance from the FDA. The product aims to improve surgical outcomes, with initial procedures yielding encouraging results. CEO Ludovic Lastennet stated that the device could quickly become essential for spine surgeons in treating adult spinal deformities.

IMPLANET, listed on Euronext Paris under the symbol ALIMP, has announced its financial information publication schedule for 2022. The schedule includes important dates such as the 2021 Full-Year Results on March 15, 2022, and subsequent quarterly revenue reports throughout the year. IMPLANET specializes in vertebral implants and employs 29 staff, achieving a consolidated revenue of €6.1 million in 2021. The company has a notable product, JAZZ®, which has received regulatory approvals including the FDA clearance in the U.S.

IMPLANET reported a strong performance for 2021, with total revenue reaching €7.7 million, marking a 29% increase, including the divested MADISON activity. The company successfully repositioned its strategy, strengthening its Spine business by 62% thanks to the acquisition of OSD. Notably, Spine revenue was €6.1 million for the year. By December 31, 2021, IMPLANET held a cash position of €1.9 million. Despite growth, challenges persisted in the US market due to COVID-19 impacting surgical scheduling.